Akamis Bio

Executive Summary

Akamis Bio is a UK-based biotechnology company established in 2020, dedicated to developing oncolytic immunotherapies for colorectal cancer. Its lead candidate, NG-350A, is a novel oncolytic virus designed to directly attack tumors while stimulating the patient's immune system. Currently in Phase 1 clinical development, NG-350A represents a potential advancement in standard of care for colorectal cancer. The company operates in a competitive landscape but focuses on a unique mechanism of action that combines tumor lysis with immune activation. With a lean organization and early-stage pipeline, Akamis Bio aims to validate its platform through ongoing clinical trials and potentially expand into other solid tumors. The company's progress hinges on successful trial outcomes and securing partnerships or additional funding to advance its programs.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 interim safety/efficacy data for NG-350A40% success
• Q4 2027Initiation of Phase 2 trial for NG-350A in colorectal cancer30% success
• Q2 2027Strategic partnership or licensing deal for NG-350A25% success